Literature DB >> 1362829

The hairless mouse model for assaying the atrophogenicity of topical corticosteroids.

R Woodbury1, A M Kligman.   

Abstract

The daily application of corticosteroids for 18 days to the dorsal skin of hairless mice resulted in loss of volume of all the cutaneous compartments. The epidermis thinned, sebaceous glands regressed, dermal thickness was reduced, horn-filled cysts shrunk, subcutaneous fat disappeared, and regression of the muscular layer occurred. The magnitude of these changes correlated strongly with the accepted potency ranking of these agents by clinical efficacy. Thus, atrophogenicity predicts anti-inflammatory activity. This model furnishes a simple screening method for assaying corticosteroid activity and for optimizing proprietary formulations.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1362829     DOI: 102340/0001555572403406

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  12 in total

1.  Test systems for the determination of glucocorticoid receptor ligand induced skin atrophy.

Authors:  Stefanie Schoepe; Heike Schäcke; Khusru Asadullah
Journal:  Dermatoendocrinol       Date:  2011-07-01

2.  Dermacase. Atrophic patches.

Authors:  Patricia Ting; Benjamin Barankin
Journal:  Can Fam Physician       Date:  2006-12       Impact factor: 3.275

3.  Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases.

Authors:  H Schäcke; T M Zollner; W D Döcke; H Rehwinkel; S Jaroch; W Skuballa; R Neuhaus; E May; U Zügel; K Asadullah
Journal:  Br J Pharmacol       Date:  2009-05-06       Impact factor: 8.739

4.  Longitudinal in vivo tracking of adverse effects following topical steroid treatment.

Authors:  Andrew J Bower; Zane Arp; Youbo Zhao; Joanne Li; Eric J Chaney; Marina Marjanovic; Angela Hughes-Earle; Stephen A Boppart
Journal:  Exp Dermatol       Date:  2016-02-13       Impact factor: 3.960

5.  Inhibition of glucocorticoid-induced epidermal and dermal atrophy with KH 1060--a potent 20-epi analogue of 1,25-dihydroxyvitamin D3.

Authors:  R Gniadecki; M Gniadecka; J Serup
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

6.  REDD1 functions at the crossroads between the therapeutic and adverse effects of topical glucocorticoids.

Authors:  Gleb Baida; Pankaj Bhalla; Kirill Kirsanov; Ekaterina Lesovaya; Marianna Yakubovskaya; Kit Yuen; Shuchi Guo; Robert M Lavker; Ben Readhead; Joel T Dudley; Irina Budunova
Journal:  EMBO Mol Med       Date:  2015-01       Impact factor: 12.137

7.  PI3K inhibitors protect against glucocorticoid-induced skin atrophy.

Authors:  Shivani Agarwal; Salida Mirzoeva; Ben Readhead; Joel T Dudley; Irina Budunova
Journal:  EBioMedicine       Date:  2019-02-05       Impact factor: 8.143

8.  Selective Activator of the Glucocorticoid Receptor Compound A Dissociates Therapeutic and Atrophogenic Effects of Glucocorticoid Receptor Signaling in Skin.

Authors:  Anna Klopot; Gleb Baida; Pankaj Bhalla; Guy Haegeman; Irina Budunova
Journal:  J Cancer Prev       Date:  2015-12-30

9.  Sexual dimorphism in atrophic effects of topical glucocorticoids is driven by differential regulation of atrophogene REDD1 in male and female skin.

Authors:  Gleb Baida; Shivani Agarwal; Ben Readhead; Joel T Dudley; Irina Budunova
Journal:  Oncotarget       Date:  2020-01-28

10.  Lycii radicis cortex inhibits glucocorticoid‑induced bone loss by downregulating Runx2 and BMP‑2 expression.

Authors:  Bina Lee; Sooyeon Hong; Minsun Kim; Eun-Young Kim; Hi-Joon Park; Hyuk-Sang Jung; Jae-Hyun Kim; Youngjoo Sohn
Journal:  Int J Mol Med       Date:  2021-06-24       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.